Drug Type Small molecule drug |
Synonyms Erythropoietin release stimulator (Insilico Medicine), Prolyl hydroxylase domain 2 (PHD2) inhibitor (Insilico Medicine) |
Target |
Action inhibitors |
Mechanism PHD2 inhibitors(egl-9 family hypoxia inducible factor 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Anemia in chronic kidney disease | Preclinical | China | 30 Jan 2022 | |
| Anemia | Preclinical | Hong Kong | 06 Jan 2021 |





